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Clinical endocrinology can be viewed as a polarized dis-
cipline. On one end of the spectrum, endocrinologists look
after patients with very common disorders such as type 2
diabetes, which constitute global health care problems of
pandemic proportions. On the other end, the specialty deals
with very rare conditions, frequently regarded as “exotic”.
Acromegaly is one of these low-prevalence conditions, yet
it has traditionally been the focus of attention of eminent
characters in the history of medicine, from neurologists like
Marie [1], to neurosurgeons like Cushing [2], to physiol-
ogists like Houssay [3]. Perhaps the reason behind such an
emphatic interest in this condition is that as rare as it can
be, acromegaly can be viewed as an in vivo model that
helps us understand a myriad of biological processes. Eti-
ologically, the molecular mechanisms responsible for the
development of GH-secreting pituitary adenomas-the ulti-
mate cause of acromegaly/gigantism in over 98 % of cases-
constitute oncogenic models that elegantly link abnormal-
ities in cell proliferation with autonomous hormonal
hypersecretion [4, 5]. Pathophysiologically, understanding
the systemic consequences of the GH/IGF-1 excess has
generated crucial knowledge in regards to issues such as
glucose metabolism, insulin resistance, vascular endothe-
lium physiology, hypertension, renal sodium handling and
even neoplasia formation [6]. Clinically, in order to ade-
quately care for the acromegaly patient, one has to be a
well-rounded internist, capable of diagnosing and treating
all the complications and co-morbidities of the disease [6].
Not less relevant is the fact that the proper management of
acromegaly should include the participation of a wide
range of specialists, from skilled pituitary neurosurgeons
and radiation oncologists, to otolaryngologists, maxillo-
facial surgeons and even psychiatrists or clinical psychol-
ogists. Undoubtedly, this multidisciplinary team has to be
coordinated by an endocrinologist with significant experi-
ence in pituitary disorders.
Since 1999, an international Acromegaly Consensus
Group, sponsored by the Pituitary Society and the Euro-
pean Neuroendocrinological Association, has met
periodically to evaluate the different aspects of acromegaly
management. As a result of these gatherings, several
reports have been published issuing guidelines and rec-
ommendations [7–12]. Although the publications derived
from the early consensus meetings do not follow a sys-
tematic, evidence-based methodology [7–9], the last three
have used the GRADE system to rank their recommenda-
tions [10–12].
The care for patients with complex diseases such as
acromegaly varies between different regions of the World
due to specific local circumstances such as the availability
of qualified specialists and economic resources to pay for
costly pharmacological treatments and radiotherapeutical
interventions. In recognition of these regional variations,
the Acromegaly Consensus Group has included the par-
ticipation of specialists from Brazil and Mexico. Latin
America cannot be considered a uniformly underdeveloped
region of the World. Although health care priorities are
somewhat different from those that prevail in Europe or the
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United States, most Latin-American Countries have tertiary
care, referral centers fully capable of caring for the patient
with acromegaly. In most instances, we find government-
based subsidized health care co-existing with private
medicine, and patients with acromegaly receive multi-
modal care at referral centers, just like in Europe and the
United States. In this regard, perhaps the main difference is
that in Latin America, medical facilities with state of the
art technology and appropriate personnel (including pitui-
tary neurosurgeons) are centralized in two or three large
cities. Thus, in Latin America, a patient diagnosed with
acromegaly has to be canalized to these referral centers
[13]. In most Latin American countries the cost of phar-
macological treatment, particularly, somatostatin analogs is
absorbed by the government. Both octreotide and lanreo-
tide depot formulations are actively commercialized and
prescribed at least in Argentina, Brazil, Chile, Colombia,
Mexico, Peru and Venezuela. The GH receptor antagonist
pegvisomant, on the other hand is utilized less frequently
due to its higher cost. Radiation therapy in most of its
modalities is probably used more frequently in the region,
because of its relatively low cost and proven efficacy.
Many of these Latin American centers are university hos-
pitals actively engaged in clinical research. With increasing
frequency, multidisciplinary groups from these centers
publish their experience in the diagnosis and management
of acromegaly. Several important Latin American publi-
cations have appeared in the medical literature, covering
the oncogenesis of somatotrophinomas [14, 15], the clini-
cal aspects of acromegaly [16] and its complications [17,
18], as well as the results of the surgical [19, 20], phar-
macological [21–24] and radiotherapeutical management
of the disease [25]. Interestingly, the outcomes of trans-
sphenoidal surgery, radiotherapy and therapy with
somatostatin analogs described in these publications are
comparable to those reached in academic institutions from
Europe and the United States [19–25].
Many Latin American specialists working in the field of
neuroendocrinology share the idea that an acromegaly
consensus adapted to the social, cultural, political and
economic realities of the region is indispensable. Such a
consensus meeting took place for the first time in Mexico
City in 2007 [26]. In October 2012 a group of specialists
from Argentina, Brazil, Colombia, Mexico and Venezuela
gathered in Oxford, United Kingdom to review the current
recommendations for the diagnosis, treatment and follow
up of acromegaly, as they pertain or apply to the com-
plexities of medical practice in Latin America. A case-
based approach was chosen to better illustrate the different
aspects of acromegaly care. Prior to the meeting, specialists
from the region were invited to submit case presentations
regarding early diagnosis, clinical presentation, identifica-
tion and treatment of co-morbidities, the role and hierarchy
of the different treatment modalities as well as the appro-
priate follow up of the disease. A steering committee
selected some of these cases for presentation and discus-
sion during the meeting. In this supplement of Pituitary we
present the most representative of these cases and analyze
the aspect of acromegaly care they allude to. We sincerely
hope that this material will help readers not only from
Latin America, but worldwide overcome the diagnostic and
therapeutic dilemmas frequently encountered in the man-
agement of this condition.
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